Catheter Ablation for Atrial Fibrillation in Patients ≤30 Years of Age

• Published in: The American journal of cardiology Vol. 166; pp. 53 - 57
• Main Authors: Yalin, Kivanc, Ikitimur, Baris, Aksu, Tolga, Ozcan, Emin Evren, Ding, Wern Yew, Soysal, Ali Ugur, Lyan, Evgeny, Eitel, Charlotte, Saygi, Serkan, Turan, Oguzhan Ekrem, Hegeer, Christian Hendrik, Tilz, Roland Richard, Gupta, Dhiraj
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2022; Elsevier Limited
• Subjects: Ablation; Adult; Age; Atrial Fibrillation - diagnosis; Atrial Flutter; Automation; Blanking; Blood clots; Cardiac arrhythmia; Cardiovascular diseases; Catheter Ablation; Catheters; Complications; Coronary artery disease; Cryosurgery - methods; EKG; Electrocardiography; Electrophysiology; Female; Fibrillation; Flutter; Genetics; Heart diseases; Hematoma; Humans; Male; Medical instruments; Patients; Pulmonary Veins - surgery; Radio frequency; Radiofrequency ablation; Recurrence; Signs and symptoms; Substrates; Tachyarrhythmia; Tachycardia; Tachycardia, Atrioventricular Nodal Reentry - diagnosis; Tachycardia, Atrioventricular Nodal Reentry - surgery; Tachycardia, Paroxysmal - surgery; Tachycardia, Supraventricular; Treatment Outcome; Vibration; Young Adult; Young adults
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2021.11.020

Pulmonary vein (PV) automaticity is an established trigger for paroxysmal atrial fibrillation (PAF), making PV isolation (PVI) the cornerstone of catheter ablation. However, data on triggers for atrial fibrillation (AF) and catheter ablation strategy in very young patients aged <30 years are sparse. A total of 51 young patients (mean age 24.0 ± 4.2 years, 78.4% men) with drug-refractory PAF underwent electrophysiology (EP) study and ablation at 5 EP centers. None of the patients had structural heart disease or family history of AF. EP study induced supraventricular tachycardia (SVT) in 12 patients (n = 12, 23.5%): concealed accessory pathway mediated orthodromic atrioventricular reentrant tachycardia in 3 patients, typical atrioventricular nodal reentrant tachycardia in 6 patients, left superior PV tachycardia in 1 patient, left atrial appendage tachycardia in 1 patient, and typical atrial flutter in 1 patient. In patients with induced SVTs, SVT ablation without PVI was performed as an index procedure, except for the patient with atrial flutter who received cavotricuspid isthmus ablation in addition to PVI. Remaining patients underwent radiofrequency (n = 15, 29.4%) or second-generation cryoballoon-based PVI (n = 24, 47%). There were no major complications related to ablation procedures. Follow-up was based on outpatient visits including 24-hour Holter-electrocardiogram at 3, 6, and 12 months after ablation, or additional Holter-electrocardiogram was ordered in case of symptoms suggesting recurrence. Recurrence was defined as any atrial tachyarrhythmia (ATA) episode >30 seconds after a 3-month blanking period. A total of 2 patients with atrioventricular nodal reentrant tachycardia, 1 with left atrial appendage tachycardia, experienced AF recurrence within the first 3 months and received PVI. After the 3-month blanking period, during a median follow-up of 17.0 ± 10.1 months, 44 of 51 patients (86.2%) were free of ATA recurrence. In the PVI group, 33 of 39 patients (84.6%) experienced no ATA recurrence. In conclusion, SVT substrate is identified in around a quarter of young adult patients with history of AF, and targeted ablation without PVI may be sufficient in the majority of these patients. PVI is needed in the majority and is safe and effective in this population.